貨號(hào)：GS40109

Burosumab is a groundbreaking, fully human monoclonal antibody specifically approved for the treatment of X-linked hypophosphatemia, a rare, inherited form of rickets and osteomalacia caused by a genetic defect in the PHEX gene. Marketed under the brand name Crysvita?, it represents the first and only therapy that targets the underlying pathophysiology of the disease rather than just supplementing phosphate and vitamin D. Burosumab is administered via subcutaneous injection and has been shown in clinical trials to significantly improve phosphate levels, bone healing, growth in children, and reduce pain and stiffness in adults.